The use of atherogenic indices as a useful marker to predict cardiovascular risk in patients with spondyloarthritis
DOI:
https://doi.org/10.18203/2349-3933.ijam20233207Keywords:
Atherogenic index, Spondyloarthritis, Cardiovascular risk, Metabolic syndrome, Castelli's risk index II, TNF inhibitorsAbstract
Background: The atherogenic index of plasma (AIP), linked to cholesterol esterification and its correlation with small dense low-density lipoprotein (LDL) levels in the blood, can predict atherosclerosis and coronary heart disease.
Methods: The study examined 45 SpA patients from the Institute of Rheumatology, RGGGH, and MMC. They underwent baseline assessments, lipid profiles, measurements, and blood tests. Atherogenic indices (AIP, Castelli's Risk I and II, atherogenic coefficient) were calculated and defined using thresholds.
Results: In this study, most patients were males (68.9%) with a mean age of 37.73. Primary ankylosing spondylitis (AS) was (62.2%), and HLAB27 was positive in 33.3% of cases. Elevated AI was prevalent: AIP>0.11 (51.1%), CR-I>3.5 (males) or >3.0 (females) (77.8%), CR-II>3.0 (26.7%), and AC>3.0 (44.4%). Significant correlations were found between AIP and waist-hip ratio (p=0.045) and AIP and fasting blood sugar [FBS] (p=0.023). High AIP was significantly associated with metabolic syndrome (21.7%) but not high disease activity. CR-I was associated with elevated FBS levels (p=0.033). CR-II was linked to higher uric acid levels (p=0.043) and current TNF inhibitor use (p=0.041), and AC showed no significant associations with the assessed factors.
Conclusions: This study underscores AI's role in assessing cardiovascular risk in spondyloarthritis patients. AIP, CR-I, and CR-II provide vital risk assessment and management insights. AIP effectively identifies metabolic syndrome, while increased Castelli's risk index II warrants further investigation in a broader population, especially among TNF inhibitor users.
Metrics
References
Crowson CS, Therneau TM, Davis JM 3rd, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum. 2013;65:2562-6.
Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:369-89.
Luchetti MM, Benfaremo D, Gabrielli A. Biologics in inflammatory and immunomediated arthritis. Curr Pharm Biotechnol. 2017;18:989-1007.
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31.
Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016;75:1016-23.
Mathieu S, Soubrier M. Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis. Ann Rheum Dis. 2019;78:e57.
Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, et al. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 2014;81:57-63.
van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998;24:663-76.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73-84.
Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis:Th17 and beyond. Arthritis &Rheumatology (Hoboken, NJ). 2014;66:231-41.
Raychaudhuri SP, Raychaudhuri SK. IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol. 2016;35:1437-41.
Bindesbøll C, Garrido-Cumbrera M, Bakland G, Dagfinrud H. Obesity increases disease activity of Norwegian patients with axial spondyloarthritis: Results from the European map of axial spondyloarthritis survey. Curr Rheumatol Rep. 2020;22:43.
Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA, et al. Atherogenic index of plasma:A useful marker for subclinical atherosclerosis in ankylosing spondylitis :AIP associate with cIMT in AS. Clin Rheumatol. 2018;37:1273-8.
Tecer D, Sunar I, Ozdemirel AE, Tural R, Kucuksahin O, Sepici Dincel A, et al. Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis? Adv Rheumatol. 2019;59:49.
Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index:Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER (HDL)) Clin Biochem. 2001;34:583-8.
Slouma M, Lahmer W, Kharrat L, Ali KB, Tezeghdenti A, Metoui L, et al. Obesity, lipid profile and cytokines in spondyloarthritis. Indian J Endocrinol Metab. 2022;26:348-53.
Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic index of plasma: Novel predictive biomarker for cardiovascular illnesses. Arch Med Res. 2019;50:285-94.
Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA, et al. Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clin Rheumatol. 2018;37:1273-80.
Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 2007;26:710-4.
Filho F, Santos AC, Silva LP, Skare MB. Lipid profile and anti-TNF-α use. Rev Bras Reumatol. 2013;53:444-7.
Tecer D, Sunar I, Ozdemirel AE, Tural R, Kucuksahin O, Sepici Dincel A, et al. Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis? Adv Rheumatol. 2019;59.
Downloads
Published
How to Cite
Issue
Section
